The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Novo Nordisk A/S (NYSE: NVO) securities between April 30, 2015 and October 27, 2016.
According to the complaint, during the Class Period, Novo Nordisk issued materially false and misleading earnings and forecasts; said reports were inflated by collusive price fixing concerning the Company’s insulin drugs. The complaint further alleges that the Company misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.
If you suffered a loss in Novo Nordisk you have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.